Wang Runsheng, Dasgupta Abhijit, Ward Michael M
Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi: 10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.
To compare the efficacy of 20 non-steroidal anti-inflammatory drugs (NSAIDs) in the short-term treatment of ankylosing spondylitis (AS).
We performed a systematic literature review of randomised controlled trials of NSAIDs in patients with active AS. We included trials that reported efficacy at 2-12 weeks. Efficacy outcomes were the change in pain score and change in the duration of morning stiffness. We also examined the number of adverse events. We used Bayesian network meta-analysis to compare effects directly and indirectly between drugs.
We included 26 trials (66 treatment arms) of 20 NSAIDs with 3410 participants in the network meta-analysis. Fifty-eight per cent of trials had fewer than 50 participants. All 20 NSAIDs reduced pain more than placebo (standardised mean difference ranging from -0.65 to -2.2), with 15 NSAIDs significantly better than placebo. Etoricoxib was superior to celecoxib, ketoprofen and tenoxicam in pain reduction, but no other interdrug comparisons were significant. There were no significant differences among NSAIDs in decreases in the duration of morning stiffness or the likelihood of adverse events. Adverse events were uncommon in these short-term studies. In 16 trials that used NSAIDs at full doses, etoricoxib was superior to all but two other NSAIDs in pain reduction.
Etoricoxib was more effective in reducing pain in AS than some other NSAIDs, but there was otherwise insufficient evidence to conclude that any particular NSAID was more effective in the treatment of AS. Comparisons were limited by small studies.
比较20种非甾体抗炎药(NSAIDs)短期治疗强直性脊柱炎(AS)的疗效。
我们对NSAIDs治疗活动期AS患者的随机对照试验进行了系统的文献综述。纳入报告了2至12周疗效的试验。疗效指标为疼痛评分变化和晨僵持续时间变化。我们还检查了不良事件的数量。我们使用贝叶斯网络荟萃分析直接和间接比较药物之间的效果。
我们在网络荟萃分析中纳入了20种NSAIDs的26项试验(66个治疗组),共3410名参与者。58%的试验参与者少于50人。所有20种NSAIDs减轻疼痛的效果均优于安慰剂(标准化均数差值范围为-0.65至-2.2),其中15种NSAIDs显著优于安慰剂。依托考昔在减轻疼痛方面优于塞来昔布、酮洛芬和替诺昔康,但其他药物间比较无显著差异。NSAIDs在晨僵持续时间减少或不良事件发生可能性方面无显著差异。在这些短期研究中,不良事件并不常见。在16项使用全剂量NSAIDs的试验中,依托考昔在减轻疼痛方面优于除其他两种NSAIDs外的所有药物。
依托考昔在减轻AS疼痛方面比其他一些NSAIDs更有效,但除此之外,没有足够证据得出任何一种特定NSAIDs在治疗AS方面更有效的结论。比较受到小规模研究的限制。